Pamiparib
A PARP inhibitor used in cancer treatment
| Pamiparib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Pamiparib is a PARP inhibitor that is used in the treatment of certain types of cancer. It is particularly utilized in the management of ovarian cancer and other malignancies associated with BRCA mutations.
Mechanism of Action[edit | edit source]
Pamiparib functions by inhibiting the enzyme poly ADP ribose polymerase (PARP). PARP plays a critical role in the repair of single-strand DNA breaks through the base excision repair pathway. By inhibiting PARP, pamiparib prevents the repair of single-strand breaks, leading to the accumulation of double-strand breaks during DNA replication. In cells with deficient homologous recombination repair mechanisms, such as those with BRCA1 or BRCA2 mutations, this accumulation of DNA damage can lead to cell death.
Clinical Use[edit | edit source]
Pamiparib is primarily used in the treatment of ovarian cancer, particularly in patients with BRCA mutations. It is also being investigated for use in other types of cancer, including breast cancer and prostate cancer. The drug is administered orally and is often used in patients who have already undergone other forms of chemotherapy.
Side Effects[edit | edit source]
Common side effects of pamiparib include nausea, fatigue, anemia, and thrombocytopenia. More serious side effects can include myelodysplastic syndrome and acute myeloid leukemia, although these are less common. Patients undergoing treatment with pamiparib require regular monitoring of their blood counts and overall health.
Development and Approval[edit | edit source]
Pamiparib was developed by BeiGene, a biotechnology company. It has undergone various clinical trials to assess its efficacy and safety in treating different types of cancer. The drug has been approved for use in several countries and continues to be the subject of ongoing research.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
